Document text
By Peter A. McCullough, MD, MPHIts fall and another season of wasted government money on unpopular and rarely taken COVID-19 boosters. The 2026–2027 boosters from Pfizer/BioNTech, Moderna, and Novavax/Sanofiall target the XFG variant— and by the time they hit pharmacy shelves this week, the variant landscape has already moved. That’s not a coincidence of timing. It’s the structural reality of chasing a nonseasonal virus that mutates faster than the regulatory approval pipeline can move. The theoretical vaccine efficacy only lasts a few months.🎯 What the Boosters Actually CoverAll three manufacturers’ 2026–2027 formulations are built around a single antigen target:Pfizer/BioNTech (COMIRNATY® XFG)— mRNA, targetsXFGModerna (Spikevax and mNexspike)— mRNA, targetsXFG, a subvariant of the JN.1 lineageNovavax (Nuvaxovid™, sold via Sanofi)— protein-based, targetsXFGThat’s it. One strain, three products. The FDA selected XFG back inMay 2026based on what was circulating in the spring. The manufacturers’ own press materials claim the shots generate responses against other lineages — XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 — but the antigen itself is XFG, and the “broadening” is theoretical cross-reactivity, not a designed match.Subscribe nowRead more